Full vaccination is imperative to suppress SARS-CoV-2 delta variant mutation frequency

Ting-Yu Yeh and Gregory P. Contreras

Auxergen Inc., Columbus Center, Institute of Marine and Environmental Technology, University of Maryland, 701 E Pratt Street, Baltimore, MD 21202, USA

*Ting-Yu Yeh is Corresponding author

E-mail: yehty@auxergen.com

Tel: 1-443-762-1974

Key words: COVID-19, SARS-CoV-2, mutation frequency, Tajima's *D* test

Short running title: Suppression of SARS-CoV-2 mutation by vaccination

Word count: 977 words.

Abstract

Public distrust has undermined COVID-19 vaccine acceptance and has become a major public health issue in the battle against SARS-CoV-2 transmission globally. Here we present the first evidence that the vaccination coverage rate is inversely correlated to the mutation frequency of the SARS-CoV-2 delta variant in 16 countries (R^2=0.878), strongly indicating that full vaccination against COVID-19 is critical to suppress emergent mutations. We also present a promising tool to forecast new COVID-19 outbreaks. The Tajima's *D* test, an evolutionary algorithm, with a threshold value of -2.50 is shown to be an accurate predictor of new outbreaks. We recommend that universal vaccination, as well as mitigation strategies, and genomic surveillance continue to be employed to prevent further viral transmission.

Introduction

Legally required vaccination against various infectious diseases is essential to public health policy in many countries. However, resistance to voluntary COVID-19 vaccination has emerged worldwide, including in the United States. In mid-June 2021, 33% of Americans said they were not willing to be vaccinated [1]. Public distrust has undermined COVID-19 vaccine acceptance, in association with a belief that the vaccine is ineffective, dangerous and compromises individual freedom [2]. Therefore, overcoming COVID-19 vaccination resistance has become a major challenge to prevent global SARS-CoV-2 transmission.

SARS-CoV-2 is characterized by an average mutation rate of 7.23 mutations per viral sample [3]. Mutations drive genome variability, generating many different SARS-CoV-2 variants as the virus evolves to escape vaccine-mediated immunity and thereby, develop drug or vaccine resistance [4]. The delta (lineage B1.617.2) variants were first documented in October 2020 in India and were designated variants of concern by the World Health Organization due to its increased transmissibility and virulence [5]. All SARS-CoV-2 mutations result from two major mechanisms: (1) spontaneous substitution/deletion of nucleotides, and (2) RNA recombination [3,4,6]. However, it remains unclear exactly how human interventions (vaccinations, lockdowns, etc.) affect viral mutations.

Findings

56 To explore this question, we first analyzed the correlation between the rates of full
57 vaccination and the point mutation frequency (*Mf*) of COVID-19 delta variants'
58 genome in 20 countries. Complete SARS-CoV-2 genome sequences with high
59 coverage from June 20 to July 3 2021 in 20 countries: Australia (*N*=121), France
60 (*N*=788), Germany (*N*=955), Indonesia (*N*=97), India (*N*=171), Ireland (*N*=617),
61 Israel (*N*=333), Italy (*N*=642), Japan (*N*=105), Mexico (*N*=368), Netherland (*N*=456),
62 Norway (*N*=142), Portugal (*N*=782), Singapore (*N*=131), Spain (*N*=689),
63 Switzerland (*N*=131), Sweden (*N*=786), Turkey (*N*=428), United States (*N*=537), and
64 United Kingdom (UK, *N*=3534) were collected from the Global Initiative on Sharing
65 All Influenza Data (GISAID)[7]. *Mf* was calculated as described previously [3]. We
66 found that *Mf* was logarithmically reduced as the full vaccination rate increased in
67 16 of the 20 countries (R^2=0.878, Figure 1A). To our knowledge, this is the first
68 evidence that vaccinations successfully suppressed viral mutations. With 10.8%
69 vaccinated rate, *Mf* was exceptionally low in Australia, likely as a result of the
70 national lockdown restrictions. In contrast, *Mf* is higher in Japan, Switzerland, and
71 United States, suggesting that their mitigation strategies have been less successful.
72
73 Previously we reported that *de novo* recombination of viral genome and positive
74 selection pressure led to prevalent SARS-CoV-2 mutations among passengers in
75 quarantine on the Diamond Princess cruise ship between January and March 2020
76 [6]. It is still unknown whether COVID-19 variants are evolving randomly or under
77 the selection pressure generated by mitigation efforts. We chronologically analyzed
78 SARS-CoV-2 delta variant sequences in the UK (*N*=27,344), India (*N*=4,451) and

79 Australia (N=305) from 13 February to 3 July 2021, respectively in the GISAID [7].
80 Genome alignments and analysis using the Tajima D test, a neutrality statistic widely
81 used in population genetics, were carried out as previously [6,8,9,10]. The Tajima D
82 test (D') compares pairwise nucleotide diversity (π, the average number of
83 nucleotide differences per site between two sequences) and total polymorphism to
84 infer selection and demographic events [6, 9, 10].
85
86 We observed that π was significantly lower in the UK ($\pi < 1.5 \times 10^{-4}$) than others
87 which emerged after April 24, 2021 ($\pi > 2.0 \times 10^{-4}$; $p<0.01$) (Figure 1B), suggesting
88 that the UK delta variants emerged with rapid clonal expansion, while others gained
89 more singleton mutations. D' value decreased drastically in both the UK and India
90 (Figure 1C). All variants eventually remained between -2.68 to -2.84 ($p<0.01$), which
91 was similar to the D' value calculated from the alpha variant sequences in UK (-2.58
92 to -2.78; N=15,396) during the period of study. Negative D' signifies stronger
93 demographic expansion or purifying (positive) selection, witnessed in both the UK
94 and Indian variants[10]. In Australia, D' decreased in June 2021, suggesting positive
95 selection exerted by lockdowns [6].
96
97 Together with available epidemiological reports [5], we found that one to three
98 weeks after D' was reduced below -2.50, new COVID-19 outbreaks emerged in the
99 UK and India (Figure 1C). Although drivers of positive selection may vary
100 (vaccinations, lockdowns, etc.), we propose that a D' score with a threshold of -2.50
101 is a promising forecasting tool for COVID-19 outbreaks. It is worth noting that D' of

102 the Australian delta variants reached -2.57 on 3 July 2021, suggesting that a further
103 extension in restrictions was required to contain outbreaks due to low vaccination
104 rates nationwide.
105
106 **Conclusion and recommendation**
107 More virulent strains of SARS-CoV-2 have emerged with enhanced transmissibility
108 and immune evasion properties. For example, multiple variants have escaped
109 neutralizing antibodies developed to target the spike protein receptor-binding or N-
110 terminal domain [11]. What's more, the case numbers of breakthrough infection
111 caused by the delta variant have increased drastically worldwide [12].
112
113 Our observations showed that countries with higher vaccination rates generated
114 fewer mutations versus low vaccinated countries. This suggests that there is less of
115 a chance for the virus to gain more virulent mutations in high vaccinated countries.
116 It must be noted that the virus becomes more contagious as it is screened through
117 the vaccinated population, eventually to become the dominant strain to infect the
118 entire population. This is what we are seeing in the delta variant in the United
119 States, the UK and many countries [12]. A negative effect of COVID-19 vaccination
120 resistance could result in a large increase of virulent mutations and failure to reach
121 herd immunity nationwide or globally.
122
123 Thus, we recommend that: 1) universal vaccination should be administered as soon
124 as possible to suppress the generation of deadly mutations; 2) mitigations strategies

such as personal protection equipment, social distancing, etc., should be re-implemented with new urgency until full vaccination is reached in an effort to prevent viral transmission until the virus is eradicated; 3) genomic surveillance should be undertaken to monitor for new mutations; and 4) The Tajima *D'* threshold test further provides a tool by which we can forecast future outbreaks.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions

All authors contributed to study concept, rationale, and initial manuscript drafts, interpretation of data, and final manuscript preparation. All authors have read and approved the final version of the manuscript.

Funding

No funding

Ethical approval

None declared.

References

1. Kirzinger A, Sparks G, Brodie M, KFF COVID-19 vaccine monitor-Rural America. https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-in-their-own-words-six-months-later/ Accessed 13 July 2021.
2. Schmelz K, Bowles S, Overcoming COVID-19 vaccination resistance when alternative policies affect the dynamics of conformism, social norms, and crowding out. Proc Natl Acad Sci U S A 2021;118(25):e2104912118. PMID: 34099578
3. Mercatelli D, Giorgi FM, Geographic and Genomic Distribution of SARS-CoV-2 Mutations. Front Microbiol 2020;11:1800. PMID: 32793182

159 4. Roy C, Mandal, SM, Mondal SK, Mukherjee S, Mapder T, et al., Trends of
160 mutation accumulation across global SARS-CoV-2 genomes: Implications for
161 the evolution of the novel coronavirus. Genomics 2020;112(6):5331-5342.
162 PMID: 33161087
163 5. The World Health organization. Tracking SARS-CoV-2 variants.
164 https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
165 6. Yeh, TY, Contreras, GP, Viral transmission and evolution dynamics of SARS-
166 CoV-2 in shipboard quarantine. Bull World Health Organ. 2021; 99(7): 486–
167 495. PMID: 34248221
168 7. Global Initiative on Sharing All Influenza Data. Available from:
169 https://www.gisaid.org/
170 8. Katoh, K, Standley, DM. MAFFT multiple sequence alignment software version
171 7: improvements in performance and usability. Mol Biol Evol.
172 2013;30(4):772–80. PMID: 23329690
173 9. Kumar S, Stecher G, Tamura K. MEGA7: Molecular evolutionary genetics
174 analysis Version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–4.
175 PMID: 27004904
176 10. Tajima F. Statistical method for testing the neutral mutation hypothesis by
177 DNA polymorphism. Genetics. 1989;123(3):585–595. PMID: 2513255
178 11. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike
179 mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-424.
180 PMID: 34075212

12. Farinholt T, Doddapaneni H, Qin X, Menon V, Meng Q, et al. Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. medRxiv 2021 Jul 12;2021.06.28.21258780. doi: 10.1101/2021.06.28.21258780. PMID: 34268529
13. Coronavirus (COVID-19) Vaccinations. Our World in Data. 2021 July. https://ourworldindata.org/covid-vaccinations

190 **Figure Legend**

191 Figure 1. (A) Correlation between full vaccinated rate [13] and mutation frequency
192 (*Mf*) from June 20 to July 3 2021 in 20 countries: Australia (AUS), France (FRA),
193 Germany (GER), Indonesia (IDA), India (IND), Ireland (IRL), Israel (ISR), Italy (ITA),
194 Japan (JPN), Mexico (MEX), Netherland (NED), Norway (NOR), Portugal (POR),
195 Singapore (SGP), Spain (ESP), Switzerland (SUI), Sweden (SWE), Turkey (TUR),
196 United States (USA), and UK. Logarithmic regression (solid) line was draw based on
197 16 countries (pink dots) with a calculated 95% confidence interval (dashed lines).
198 Japan, Switzerland, USA, and Australia are labeled in different colors as outliers. (B
199 and C) Chronology of nucleotide diversity (π) (B) and Tajima *D'* value (C) of SARS-
200 CoV-2 delta variants in UK (*N*=27,344, blue), Indian (*N*=4,451, red), and Australian
201 (*N*=305, green). Data were plotted every two weeks, and the data only represent
202 the effective population size with more than 3 high quality sequences. The arrows
203 label the epidemiological events of COVID-19 delta variants announced by the
204 World Health Organization (WHO). WHO classified the delta variant as a global
205 variant of interest (VOI) on 4 April 2021, and variants of concern (VOC) on 11 May
206 2021 [5]. The dashed line in (C) labels the cut-off threshold -2.50 in Tajima *D'* test.


A
Mutation frequency (Mf)
Fully vaccinated rate
IND
JPN
IDA
SUI
USA
MEX
NOR
NED
TUR
FRA
AUS
SGP
GER
ITA
ESP
POR
SWE
ISR
IRL
UK
B
Nucleotide diversity (π)
UK
India
Australia
April 4
Delta(VOI)
May 11
Delta (VOC)
UK COVID-19
case increase
C
Tajima D' value
UK (N=27,334)
India (N=4,451)
Australia (N=305)
April 4
Delta(VOI)
May 11
Delta (VOC)
UK COVID-19
case increase

207